Report from the Annual General Meeting
25 November, 2021
Today, November 25, 2021, the Annual General Meeting of DexTech Medical AB was held. Below is a summary of the decisions made. All decisions were made by the required majority.
Decision on adoption of income statement and balance sheet
The AGM resolved to approve the presented income statement and balance sheet.
Decision on dispositions regarding the company’s profit according to the approved balance sheet
The AGM resolved to dispose of the company’s results, and that no dividend be paid for the financial year 2020/2021.
Resolution on discharge from liability for the members of the Board of Directors and the President
The AGM resolved on discharge from liability for the members of the Board and the President.
Determination of the number of board members and deputy board members
The AGM resolved that the number of board members shall be unchanged at five members and that no deputies be elected.
Determination of fees for the board and auditors
The AGM resolved that board fees shall not be paid and that fees to the auditor shall be paid in accordance with approved invoices.
Election of board and auditor
The AGM resolved to re-elect Svante Wadman, Anders Holmberg, Sten Nilsson, Per-Olof Asplund and Rolf Eriksson. At the subsequent statutory Board meeting, Svante Wadman was re-elected Chairman of the Board. KPMG AB, with Per Hammar as responsible auditor, was re-elected as auditor for the period until the end of the next Annual General Meeting.
For further information
Gösta Lundgren – CFO
DexTech Medical AB
Phone: +46 (0) 707104788
The information was submitted, through the agency of the above contact person, for publication on November 25, 2021.
DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with skeletal metastases. A successful clinical phase II study has been conducted with OsteoDex where the results show high tolerability with mild side effects and treatment effect on patients who fail existing drugs. DexTech’s goal is to outlicense the respective drug candidate no later than after the completion of a phase II study. DexTech Medical AB is listed on the Spotlight Stock Market.